Theratechnologies

Cellino and Karis Bio Partner to Develop First Autologous iPSC Therapy for Cardiovascular Disease

a month ago

• Cellino and Karis Bio have formed a strategic partnership to industrialize the world's first clinical-stage autologous iPSC-derived cell therapy for peripheral and coronary artery diseases. • The collaboration leverages Cellino's Nebula platform for scalable iPSC production and Karis Bio's vessel regeneration technology to offer patients an alternative to invasive procedures while eliminating immune rejection risks. • This partnership marks Cellino's expansion into the Asia-Pacific region, with initial focus on manufacturing optimization before advancing to Phase 2 trials through Karis Bio's U.S. operations.

FDA Approves EGRIFTA WR™: New Weekly Reconstitution Formulation for HIV-Associated Lipodystrophy

2 months ago

• Theratechnologies has received FDA approval for EGRIFTA WR™ (tesamorelin F8), a new formulation that requires weekly rather than daily reconstitution for treating excess visceral abdominal fat in adults with HIV and lipodystrophy. • The improved formulation requires less than half the administration volume of the current EGRIFTA SV® version, offering a more convenient patient experience while maintaining bioequivalence to the original tesamorelin formulation. • Recent data presented at CROI 2025 highlights that BMI alone is insufficient for assessing cardiovascular risk in HIV patients, emphasizing the importance of measuring visceral adipose tissue in this population.

Sudocetaxel Zendusortide Shows Promise in Advanced Ovarian Cancer Phase 1b Trial

6 months ago

• Theratechnologies' sudocetaxel zendusortide demonstrates favorable tolerability and efficacy signals in heavily pre-treated ovarian cancer patients in a Phase 1b trial. • No dose-limiting toxicities were observed in patients receiving weekly doses of sudocetaxel zendusortide, indicating a manageable safety profile. • Preliminary efficacy data showed significant tumor shrinkage and complete resolution of a liver lesion in some patients at a 2.5-mg/kg/week dose. • The Medical Review Committee recommends further evaluation and exploration of higher doses based on the encouraging tolerability and efficacy data.